MPI Cognition

MPI Cognition was a private U.S. healthcare technology and precision health company focused on dementia prevention and reversal of cognitive decline. Operating as the commercial vehicle for Metabolic Programmatics, it provided advanced medical information, diagnostic testing support, practitioner training, and algorithm-guided care centered on Dr. Dale Bredesen's protocol for Alzheimer's disease and related cognitive impairment. The business emphasized a multimodal, personalized intervention approach rather than developing conventional therapeutic drugs. MPI Cognition appears to have been acquired in 2018 by AHNP Precision Health, which later operated as Apollo Health. It was therefore more of a health services and protocol commercialization company than a traditional biotech drug developer.